Dr Azim Khan

MBBS, FRACP

Dr. Azim Khan is a Medical Oncologist working at WACHS – Northam Regional Hospital, Hollywood Private Hospital, and the Breast Cancer Research Institute, WA. He manages a broad spectrum of cancers, with expertise in breast, genitourinary, gastrointestinal, lung cancers, melanoma, and cancer immunotherapy.

Clinical Roles & Leadership

Dr. Khan is Head of Cancer Services at Northam Regional Hospital and has served briefly as Acting Medical Director of Oncology for WACHS. He transformed the oncology service at Northam from a one-day clinic into a comprehensive five-day cancer care program. He established multidisciplinary team (MDT) pathways, introduced complex systemic therapies in a regional setting, and developed a skilled nursing and nurse practitioner workforce, significantly improving local access to high- quality cancer care.

Training & Fellowships

Dr. Khan completed his specialist training in Medical Oncology at Sir Charles Gairdner Hospital and Fiona Stanley Hospital. He was awarded a competitive WA Palliative Care Network research fellowship and completed a Clinical Research Fellowship in Breast and Genitourinary Cancers under highly experienced mentors. Driven by his interest in geriatric oncology, he subsequently completed an additional fellowship in this field to address unmet needs in the care of older cancer patients, completing his fellowships in 2021.

Research & Achievements

Awarded a Research Grant (2020) through Fiona Stanley Hospital for studying sarcopenia and immunotherapy associations. WACHS Wheatbelt Employee of the Year Award (2021) in the Compassion category. Multiple publications in high-impact journals, including Journal of Clinical Oncology, Cancer Research, Cancers, and Annals of Oncology.

Developed a tailored predictive algorithm to improve outcomes and reduce mortality in geriatric Indigenous women with breast cancer in Western Australia. Presented research at major international conferences, including ESMO, ASCO, San Antonio Breast Cancer Symposium, and dedicated breast cancer meetings.

Actively involved in cancer clinical trials, including immunotherapy, antibody-drug conjugates (ADCs), T-cell engagers, and tumor-infiltrating lymphocytes (TILs). Principal Investigator in Phase I–III trials, including a Phase III mRNA vaccine trial in adjuvant bladder cancer and the Litespark Trial in kidney cancer. Leads ongoing trials in aggressive triple-negative breast cancer and multiple breast cancer phenotypes, including studies focused on Indigenous women.

Actively contributes nationally on committees to improve cancer care in the geriatric population, collaborating with colleagues across Australia to develop standards and pathways for better outcomes.

Dr. Khan’s clinical and research efforts focus on improving cancer care outcomes in both regional and underserved populations, bridging advanced cancer therapies with community access.